Synpromics was founded to commercialise proprietary and patent-pending technology, developed by Dr Michael Roberts, in the emerging field of synthetic biology.

Synpromics gives biological researchers, developers and manufacturers unprecedented control of gene expression through the ability to create an unlimited portfolio of man-made DNA sequences, each of which can be patented. This is a highly disruptive technology as most of the currently used promoters are natural viral or gene specific promoters.

Synpromics’ products will comprise, or be based on, patented synthetic promoters that are designed to regulate genes in a highly specific manner. Given that the Company’s products will greatly improve upon the natural promoters on which the entire biotech industry currently relies to regulate genes, there is enormous potential to transform the sector.